Arcus reports ARC-20 Phase 1/1b data: pooled ORR 31%, median PFS 12.2 mo; unveils 5 I&I preclinical programs

Arcus Biosciences, Inc.

ARC-20 pooled analysis (n=121) in ccRCC: 31% confirmed ORR [95% CI 23-40], median PFS 12.2 mo (9.4-20.6).
50 mg QD cohort showed 36% ORR (incl. pending) and median PFS 19.2 mo; 100 mg QD showed 42% ORR (incl. pending).
Safety: Grade≥3 anemia 41%, hypoxia 11%; discontinuation rate 3%; no unexpected signals as of Aug 15, 2025 DCO.
Five new preclinical programs disclosed: MRGPRX2, TNFR1, CCR6, CD89, CD40L; first clinical study targeted in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.